The underlying mechanisms of idiopathic pulmonary fibrosis (IPF) are unknown. Th is progressive disease has high mortality rates, and current models for prediction of mortality have limited value in identifying which patients will progress. We previously showed that the glycoprotein fi bulin-1 is involved in enhanced proliferation and wound repair by mesenchymal cells and, thus, may contribute to lung fi brosis in IPF.
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Materials and Methods
Th is study contained three components. First we measured serum and lung tissue levels of fi bulin-1 in patients with IPF and from individuals without lung disease. Next, we used fi broblast cultures to assess fi bulin-1 production. Finally, we explored the utility of serum fi bulin-1 as a biomarker of disease progression.
Study Approvals
Th is study was approved by the ethics committees of each of the six institutions involved in three countries; informed, written consent was obtained from all participants or their next of kin. Detailed ethics information can be found in e-Appendix 1 .
Fibulin-1 Levels in Serum
Serum was collected from three independent populations in Sydney, NSW, Australia; San Francisco, CA; and Modena, Italy, and included 72 patients with IPF and 17 individuals without lung disease ( Table 1 ) . A diagnosis of IPF was determined by multidisciplinary review as recommended by current guidelines. 16 Detailed characteristics of the three cohorts of patients with IPF are found in e- Table 1 . Characteristics of 79 additional patients with ILD are found in e- Table 2 . Diagnoses included sarcoidosis (n 5 12), hypersensitivity pneumonitis (n 5 32), and "other" ILDs defined as connective tissue diseaserelated ILD (n 5 26), nonspecific interstitial pneumonia (n 5 4), lymphangioleiomyomatosis (n 5 4), and drug-induced ILD (n 5 1). Fibulin-1 levels were measured using densitometric analysis of western blots compared with a placental fi bulin-1 positive control.
Fibulin-1 Levels in Tissue
Lung parenchymal tissue was collected from four independent cohorts: Sydney, NSW, and Perth, WA, Australia; San Francisco, CA; and Modena, Italy. Lung function was measured within 30 days of tissue sampling. Characteristics of patients used for analysis of formalin-fi xed lung tissue are found in Table 2 , while those for patients used for whole-lung lysate analysis were not available. Fibulin-1 levels were measured by quantifi cation of immunohistochemical staining ( e -Fig 1 ) or western blot, respectively. Measurement of total collagen by quantifi cation of Masson Idiopathic pulmonary fi brosis (IPF) is the most common of the idiopathic interstitial lung diseases (ILDs) and has the highest mortality. 1 Forty-four percent of all patients with IPF are expected to die within 5 years, compared with 33% of patients with ILDassociated connective tissue disease and 2% of patients with pulmonary sarcoidosis, two other ILDs. 1 Treatments for IPF have been largely unsuccessful, 2, 3 mainly because the underlying mechanisms of IPF are unresolved and there is no biomarker available to pinpoint individuals with the risk of accelerated disease progression. Biomarkers in IPF refl ecting states of active fi brogenesis in the lung are needed to indicate those patients who will rapidly decline, so as to prioritize them for intensive management care and lung transplantation.
It is likely that common pathways driving fi brogenesis exist in many diseases with a fi brotic component. 4 Th e composition of the extracellular matrix (ECM) is an important and unifying factor in the pathophysiology of fi brosis, including lung fi brosis. 5 A number of ECM proteins also circulate in the blood. However, the utility of bloodborne ECM proteins as serum biomarkers in IPF has not been well investigated. 6, 7 Th is refl ects our lack of knowledge as to which components of the ECM contribute particularly to the disease pathology of pulmonary fi brogenesis and progression of the disease.
Th e glycoprotein fi bulin-1, which is found in both the ECM and the blood, is necessary for embryonic morphogenesis 8 and is essential for alveolar septa formation. 9 It is widely accepted in the literature that there are similarities between the development of fi brosis and embryonic morphogenesis, 10 concepts not limited to the lung. 11 Fibulin-1 is produced by lung fi broblasts 12 and has been shown to play a role in the pathophysiology of patients with asthma, 13 a disease characterized in part by airway fi brosis. 14 We reasoned that dysregulated fi bulin-1 expression may be involved in lung diseases with more extensive fi brosis as mechanisms of fi brogenesis are likely to be shared. 15 Th is study explored the role of fi bulin-1 in disease pathogenesis and progression of IPF. To this aim, we examined serum and tissue fi bulin-1 levels in patients with IPF and related it to lung function. We measured fibulin-1 production by lung fi broblasts derived from patients with IPF and from subjects without lung fi brosis. Lastly, we investigated whether serum fi bulin-1 could serve as a biomarker and assessed its prognostic utility in several cohorts of patients with IPF. trichrome staining was used as a positive control for fi brosis in tissue sections.
Fibulin-1 Levels in Parenchymal Fibroblasts
Human distal parenchymal fi broblasts were isolated from lung tissue obtained from patients with IPF (n 5 8) or pathologist-identifi ed macroscopically nondiseased tissue from age-matched and sex-matched donors (n 5 7) undergoing resection for either thoracotomy or transplantation. Demographic information for people from whom fi broblasts were derived is found in e- Table 3 . Lung function measurements and smoking history were not available. Fibulin-1 levels were measured by western blot.
Serum Fibulin-1 as a Biomarker of Disease Progression
Patients with IPF were followed up for a minimum of 1 year (365 Ϯ 1 day) aft er blood draw. A progression event was defi ned as any of the following occurring within the fi rst 1-year follow-up period: Ն 10% relative fall in % predicted FVC, Ն 15% relative fall in % predicted diff using capacity of the lung for carbon monoxide (D lco ), or death, as previously published. 17 
Statistics
Statistical analysis was performed using SPSS (Version 21) (IBM).
The coefficient of repeatability and intraclass correlation coefficient were calculated. 18 Distributions of serum, parenchyma, and fi broblast levels of fi bulin-1, and lung function parameters were tested for normality. Receiver-operator characteristic (ROC) curves were used to model the utility of serum fi bulin-1 as a marker of disease progression. Cox regression analysis was used to model the impact of serum fi bulin-1 levels on predicting progression. Kaplan-Meier curves were used to model time-to-progression event. Correlations between fi bulin-1 and lung function parameters in patients with IPF were performed using Pearson product-moment tests. Between-group diff erences were assessed by unpaired t , Kruskal-Wallis, Fisher exact, x 2 , and log-rank tests, or analysis of covariance where appropriate. A P value Յ .05 was considered signifi cant. Additional methods can be found in e-Appendix 1 .
Results
Serum Fibulin-1 Levels Are Increased in Patients With IPF
Serum fibulin-1 levels were significantly higher in patients with IPF compared with subjects without lung disease aft er adjustments for potential confounding variables: age, sex, and smoking history ( Fig 1 , e- Table 4 ) . Th e serum fi bulin-1 levels were comparable in the three independent populations of patients with IPF ( e- Table 1 ) . Serum fi bulin-1 levels were also increased in patients with IPF compared with patients with sarcoidosis, and patients with other ILDs, but there was no diff erence compared with patients with hypersensitivity pneumonitis ( e -Fig 2 , e- Table 4 ). Serum fibulin-1 levels did not correlate with lung function variables in patients with only IPF ( e- Table 5 ) but did correlate with lung function when all ILDs were included in the analysis ( e -Fig 3 , e- Table 6 ).
Tissue Fibulin-1 Levels Are Higher in Patients With IPF
Th e level of fi bulin-1 in whole-lung lysates from patients with IPF (mean, 3.43 units; SD, 0.91) was 2.6-fold higher than in subjects without lung disease (mean, 1.34; SD, 0.2; P 5 .02) ( Fig 2A ) . Representative images of fi bulin-1 and Masson trichrome-stained tissue from patients with IPF and subjects without lung disease are shown in Figure 2B . Th e level of fi bulin-1 in formalin-fi xed tissue sections was signifi cantly higher in patients with IPF (mean, 129.2 units; SD, 4.32) compared with subjects without lung disease (mean, 118.6; SD, 3.73; P , .001) ( Fig 2C ) . Th ere was no signifi cant diff erence in fi bulin-1 levels in explanted lung tissue ( P 5 .24) ( Fig 2C ) . More collagen (percentage area stained with Masson trichrome) was measured in tissue from patients with IPF (n 5 12; mean, 25.0% area; SD, 10.5) than in tissue from subjects without lung disease (n 5 5; mean, 12.1; SD, 6.4; P 5 .02) ( Fig 2D ) . To investigate a potential source of the increase in fi bulin-1, we compared the secreted and cell-associated levels of fi bulin-1 in primary parenchymal fi broblasts from patients with IPF with age-matched and sex-matched subjects without lung disease under nonstimulated cellculture conditions in fi broblasts at low passage number (at most fi ve passages). Fibroblasts derived from patients with IPF produced signifi cantly more secreted fi bulin-1 than fi broblasts from subjects without IPF ( P 5 .003) ( Fig 4A ) . Fibroblasts from patients with IPF produced more cell-associated fi bulin-1 than fi broblasts derived from subjects without IPF ( P 5 .007) ( Fig 4B ) .
Serum Fibulin-1 Predicts Progression in IPF
Of the 72 patients with IPF, 48 patients were available for 1-year follow-up. In the year following blood draw, 27 patients had a progression event and 21 patients remained stable. Patients who later progressed had poorer D lco , CPI, and TLC at the time of blood draw than those who did not progress ( Table 1 ) . Th ere was no diff erence in FEV 1 , FVC, age, sex, or history of smoking between the two groups.
Serum fi bulin-1 levels were 1.5 times higher in patients with IPF who experienced a progression event (mean 2.34 units, SD 1.18) compared with patients who remained stable (mean 1.59 units, SD 0.83; P 5 .013) ( Table 1 ) . Th e area under the ROC curve was 0.71 (95% CI, 0.57-0.86; P 5 .012) ( Fig 5A ) . From this curve, thresholds for fi bulin-1 levels were generated and sensitivity and specifi city at each fi bulin-1 level were estimated. Th ree thresholds (1.1, 1.6, and 2.9) were chosen for their diff ering specifi city and sensitivity profi les and subjected to further analysis. At a threshold of 1.6 units, serum fi bulin-1 identifi ed patients with IPF who progressed with 70% sensitivity and 71% specifi city. At thresholds of 1.1 and 2.9 units, the sensitivities and specifi cities were 93% and 33%, and 30% and 90%, respectively ( e- Table 7 ). Kaplan-Meier curves showed that patients with IPF with a serum fi bulin-1 level . 1.6 units had a shorter progression-free survival time than those with Յ 1.6 units ( P 5 .003) ( Fig 5B , Table 3 ). The progression-free survival rates of patients with IPF with high or low serum fi bulin-1 levels were also signifi cantly diff erent if thresholds of 1.1 units or 2.9 units were used to stratify the groups (1.1 units, P 5 .016; 2.9 units, P 5 .019) ( Table 3 ). An increase in 1 unit of serum fibulin-1 level in patients with IPF carried a significant hazard ratio for the likelihood of disease progression of 1.69 (95% CI, 1.2-2.3; P 5 .001).
Figure 2 -Tissue fi bulin-1 and collagen levels in lung parenchyma from IPF and nondiseased subjects. A, Levels of fi bulin-1 in lysates of parenchyma from patients with IPF (n 5 4) and nondiseased subjects (n 5 4) were analyzed by western blot and densitometric values were normalized to GAPDH detected on the same blots. A representative blot is shown. Lane 1, Cell lysate from fi bulin-1 transfected HT1080 fi brosarcoma cells. Total protein (1.5 m g) of whole-lung lysates from nondiseased subjects (lanes 2-5) and patients with IPF (lanes 6-9) were loaded. B, Th e normalized densitometric values were compared by unpaired t test; *P , .05. C-F, Immunostaining of fi bulin-1, detected using a chemical chromophore DAB (brown) and Masson trichrome staining for detection of collagen (green) in formalin-fi xed tissue sections from patients with IPF and nondiseased subjects was analyzed by computerized image analysis. Twenty images were taken at random from two to six sections per patient (fi bulin-1 IPF: n 5 5 explanted lungs, n 5 15 surgical biopsies, nondiseased subjects n 5 5; collagen IPF: n 5 12 surgical biopsies, nondiseased subjects n 5 5). Representative images in nondiseased subjects (C, fi bulin-1; D, collagen) and patients with IPF (E, fi bulin-1; F, collagen). In images, black triangle indicates airway, black solid arrow indicates blood vessel, black dashed arrow indicates alveolar septa. Fibulin-1 staining is distributed throughout the lung parenchyma but may be more concentrated in cells within the alveolar space (black lightning bolt). G-H, Averaged staining levels for (G) fi bulin-1 and (H) collagen were compared using analysis of variance (**P 5 .005, fi bulin-1) and unpaired t test (*P , .05, collagen). Values are expressed in all graphs
Univariate logistic regression showed that age, history of smoking, or FVC did not predict disease progression in our study population. When the variables serum fi bulin-1, age, history of smoking, FVC, and D lco were analyzed simultaneously in the multivariate model, the independent contribution of serum fi bulin-1 increased to 2.11 (95% CI, 1.3-3.5; P 5 .004) ( e- Table 8 ). D lco did not predict disease progression in the multivariate model.
A patient with IPF with a level of serum fi bulin-1 . 1.6 units was five times more likely to progress compared with a patient with a level of serum fibulin-1 Յ 1.6 units (hazard ratio, 5.2; 95% CI, 2.0-13.3; P 5 .001).
Discussion
To our knowledge, this is the fi rst study reporting the signifi cance of fi bulin-1 in the severity and disease progression of IPF. Th e increased levels of fi bulin-1 found in the serum, lung tissue, and primary fi broblast cultures of patients with IPF indicate fi bulin-1 may contribute to this disease and importantly, a high serum fi bulin-1 level may serve as a biomarker for disease progression. Moreover, the fi ndings of this study were derived from four separate patient cohorts from three diff erent countries, which is important, as IPF is a variable and global disease.
We have previously observed raised fi bulin-1 levels in the serum and BAL fl uid of patients with asthma, 13 a disease in which fi brosis of the airways is associated with disease progression. 14 Across diseases in which fi brosis occurs there are similar mechanisms contributing to fi brogenesis. 15 Hence, it was logical to explore whether fi bulin-1 would also be important in a disease predominantly characterized by fi brosis, that is, IPF. Alterations in fi bulin-1 levels have been observed in a number of diseases. Plasma levels of fi bulin-1 were identifi ed as a potential marker for kidney malfunction, 19 and increased levels of fi bulin-1 were detected in sera from patients with preeclampsia. 20 It is likely that the feature common to these diseases and the lung disease we studied is active fi brosis.
If fi bulin-1 were to be biologically important during active fi brosis, then levels of fi bulin-1 would likely be related to measurements of disease severity. While much of the focus in the literature has centered on the importance of collagen to fi brosis, 21 it is possible that smaller ECM-connecting proteins, 22 like fi bulin-1 which binds to elastic fi bers, 12 can also act to alter the mechanical properties of the lung. 23 In this study, as the levels of tissue fi bulin-1 increased, the lung function of the patients decreased. Given that fi bulin-1 is a known modulator of the ECM during the progression of some diseases, 24 this fi nding is indicative of the potential importance of fi bulin-1 as a target during fi brogenesis. Patients with IPF who presented with a high level of serum fi bulin-1 had a shorter progression-free survival time compared with those who had a low level of serum fi bulin-1. The progression-free survival time of patients who presented with a high level of fi bulin-1 (greater than the threshold of 1.1, 1.6 or 2.9) and low level of fi bulin-1 (less than or equal to the threshold of 1.1, 1.6 or 2.9) were compared using the Mantel-Cox log-rank test. See Table 1 legend for expansion of abbreviation.
Primary parenchymal fi broblasts derived from patients with IPF produced more secreted and cell-associated fi bulin-1 than fi broblasts derived from patients without IPF. Th e contribution of particular ECM molecules to the development of fi brogenesis has not been extensively investigated in IPF, as research has largely focused on either chemokines or circulating progenitors of myofi broblasts as targets to dampen the "profi brotic environment" that drives fi brosis. 25 Furthermore, there is evidence that the stiff ness of the underlying matrix alters fi broblast behavior. 26 It is possible that excessive production of secreted fi bulin-1 by the resident fi broblasts of patients with IPF contributes to the increased fi bulin-1 level found in the blood. In addition, the increased production of fi bulin-1 likely refl ects in the activated fibrogenic state of fibroblasts derived from patients with IPF.
A number of serum biomarkers of disease severity and progression in IPF have been identifi ed and reviewed. 6, 7 Th ese include the MUC5B gene polymorphism, 27 mucin-1 (KL-6), surfactant proteins SP-A and SP-D, matrix metalloproteinases 1 and 7, chemokines CCL18 and CXCL8, calgranulin B (S100A12), intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1), and periostin. 28 While it is likely that numerous factors will contribute to the development of fi brosis, the strength of our focus on fi bulin-1 is the consistent fi nding in multiple patient cohorts and the multiple forms, soluble and tissue incorporated, of the protein that were increased. In addition, lung tissue fibulin-1 levels relate to physiologic measurements of lung function in patients with IPF.
An important finding from this study for the future management of IPF is the observation that serum fi bulin-1 levels have predictive value for acute disease progression in patients with IPF. There was a 71% chance that there was a higher serum fibulin-1 level in a patient with IPF who progressed within 1 year compared with a patient who remained stable. In addition, patients with a high level of serum fibulin-1 had a higher likelihood of progression and a shorter progression-free survival time compared with their low fibulin-1 counterparts. Serum levels were highest in patients with IPF compared with patients with other ILDs but correlated with lung function variables in all patients with ILD, suggesting that serum fi bulin-1 levels may predict disease progression in other fibrosing ILDs, such as idiopathic nonspecific pneumonia.
It is crucial to identify factors able to categorize which patients with IPF will rapidly decline compared with those patients with a more stable form of the disease.
Further follow-up studies in a larger sample size are needed to confi rm the potential use of fi bulin-1 levels for the stratifi cation of patients with IPF. Th is information will enable clinicians to optimize early referral to transplantation programs and palliative care. Fibulin-1 may be a useful tool to stratify patients for inclusion in future therapeutic trials and to guide future management decisions.
